The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Coherus Oncology Inc shares valued at $73,881 were sold by Wahlstrom Mats on May 23 ’25. At $0.74 per share, Wahlstrom Mats sold 99,988 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.
As published in a research note from UBS on August 16, 2024, Coherus Oncology Inc [CHRS] has been rated down from a Buy to a Neutral and the price target has been revised to $1.50 from $4. Analysts at Robert W. Baird started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid November. As of November 08, 2023, Maxim Group has decreased its “Buy” rating to a “Hold” for CHRS. Earlier on July 24, 2023, Citigroup initiated its rating. Their recommendation was “a Buy” for CHRS stock.
Analyzing CHRS Stock Performance
On last trading session,, Coherus Oncology Inc [NASDAQ: CHRS] plunged -1.80% to $0.79. The stock’s lowest price that day was $0.7602, but it reached a high of $0.8091 in the same session. During the last five days, there has been a drop of approximately -1.90%. Over the course of the year, Coherus Oncology Inc shares have dropped approximately -42.72%.
Support And Resistance Levels for Coherus Oncology Inc (CHRS)
RSI (Relative Strength Index) is 43.71 on the 14-day chart, showing neutral technical sentiment.
Is Coherus Oncology Inc subject to short interest?
Stocks of Coherus Oncology Inc saw a sharp steep in short interest on 2025-05-30 dropping by 31907.0 shares to 32.53 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 32.57 million shares. A decline of -0.1% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 21.43 of the overall float, the days-to-cover ratio (short ratio) decline to 21.43.
